Literature DB >> 20235743

Anthropometric measurements and diabetes mellitus: clues to the "pathogenic" and "protective" potential of adipose tissue.

Harold E Bays1, Kathleen M Fox, Susan Grandy.   

Abstract

BACKGROUND: Increased visceral adipose tissue (VAT) is "pathogenic" through adverse endocrine and immune contributions to metabolic diseases such as diabetes mellitus, hypertension, and dyslipidemia. Increased VAT increases waist circumference (WC), and WC is a recommended anthropometric measure of pathogenic adipose tissue distribution. Increased subcutaneous adipose tissue (SAT) is often described as "protective" against metabolic disease and frequently approximated by hip circumference (HC).
METHODS: The Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD) evaluated a study sample weighted to reflect the U.S. adult population. Respondents diagnosed with type 2 diabetes mellitus (T2DM; n = 3825) and without T2DM (n = 13,327) self-reported their weight and height, WC, and HC.
RESULTS: T2DM men and women had a disproportionate increase in body mass index (BMI) and WC, with 30% of T2DM men and 40% of T2DM women having a WC within the highest quintile compared to the overall study population. Waist-to-hip ratio (WHR) appeared to be the best anthropometric predictor of T2DM. However, both T2DM men and women also had a disproportionate increase in HC, with 30% of T2DM men and 34% of T2DM women having a HC within the highest quintile, which was generally similar to the distribution of BMI and WHR.
CONCLUSIONS: This analysis suggests that: (1) An increase in adipose tissue generally increases the risk of T2DM; (2) central adiposity is more pathogenic than peripheral subcutaneous adiposity; and (3) SAT accumulation, as assessed by increased HC, does not always "protect" against metabolic diseases such as T2DM.

Entities:  

Mesh:

Year:  2010        PMID: 20235743     DOI: 10.1089/met.2009.0089

Source DB:  PubMed          Journal:  Metab Syndr Relat Disord        ISSN: 1540-4196            Impact factor:   1.894


  8 in total

1.  Abdominal superficial subcutaneous fat: a putative distinct protective fat subdepot in type 2 diabetes.

Authors:  Rachel Golan; Ilan Shelef; Assaf Rudich; Yftach Gepner; Elad Shemesh; Yoash Chassidim; Ilana Harman-Boehm; Yaakov Henkin; Dan Schwarzfuchs; Sivan Ben Avraham; Shula Witkow; Idit F Liberty; Osnat Tangi-Rosental; Benjamin Sarusi; Meir J Stampfer; Iris Shai
Journal:  Diabetes Care       Date:  2012-02-16       Impact factor: 19.112

2.  Fat distribution and glucose intolerance among Greenland Inuit.

Authors:  Marit Eika Jørgensen; Knut Borch-Johnsen; Ronald Stolk; Peter Bjerregaard
Journal:  Diabetes Care       Date:  2013-05-08       Impact factor: 19.112

Review 3.  Adiposopathy, "sick fat," Ockham's razor, and resolution of the obesity paradox.

Authors:  Harold Bays
Journal:  Curr Atheroscler Rep       Date:  2014-05       Impact factor: 5.113

4.  Contribution of subcutaneous abdominal fat on ultrasonography to carotid atherosclerosis in patients with type 2 diabetes mellitus.

Authors:  Chan-Hee Jung; Bo-Yeon Kim; Kyu-Jin Kim; Sang-Hee Jung; Chul-Hee Kim; Sung-Koo Kang; Ji-Oh Mok
Journal:  Cardiovasc Diabetol       Date:  2014-03-28       Impact factor: 9.951

5.  Visceral adipose tissue but not subcutaneous adipose tissue is associated with urine and serum metabolites.

Authors:  Inga Schlecht; Wolfram Gronwald; Gundula Behrens; Sebastian E Baumeister; Johannes Hertel; Jochen Hochrein; Helena U Zacharias; Beate Fischer; Peter J Oefner; Michael F Leitzmann
Journal:  PLoS One       Date:  2017-04-12       Impact factor: 3.240

6.  Relations of Visceral and Abdominal Subcutaneous Adipose Tissue, Body Mass Index, and Waist Circumference to Serum Concentrations of Parameters of Chronic Inflammation.

Authors:  Inga Schlecht; Beate Fischer; Gundula Behrens; Michael F Leitzmann
Journal:  Obes Facts       Date:  2016-06-01       Impact factor: 3.942

7.  Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults.

Authors:  Ian J Neeland; Colby R Ayers; Anand K Rohatgi; Aslan T Turer; Jarett D Berry; Sandeep R Das; Gloria L Vega; Amit Khera; Darren K McGuire; Scott M Grundy; James A de Lemos
Journal:  Obesity (Silver Spring)       Date:  2013-05-19       Impact factor: 5.002

Review 8.  Central obesity as a clinical marker of adiposopathy; increased visceral adiposity as a surrogate marker for global fat dysfunction.

Authors:  Harold Bays
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-10       Impact factor: 3.243

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.